PTC Jumps Most Since 2014 as U.K. Regulator Recommends DMD Drug
PTC Therapeutics Inc. soared the most since May 2014 after the U.K.'s health-cost regulator recommended its drug for a deadly muscle disease. The U.K.'s National Institute for Health and Care Excellence, known as NICE, recommended PTC's drug Translarna for some patients with Duchenne muscular dystrophy in England, according to a statement Friday.
from Biotech News